Osprey Private Wealth LLC Invests $2.24 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Osprey Private Wealth LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,530 shares of the biopharmaceutical company's stock, valued at approximately $2,239,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $25,000. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares in the last quarter. Tompkins Financial Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Finally, Curat Global LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 1.4%

NASDAQ REGN traded up $7.40 during trading hours on Friday, reaching $529.24. The company had a trading volume of 951,512 shares, compared to its average volume of 877,247. The stock has a 50-day moving average of $563.74 and a 200 day moving average of $651.53. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $57.14 billion, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the company earned $9.55 EPS. The company's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on REGN. Bank of America dropped their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday, June 2nd. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a report on Monday, June 2nd. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.